MXPA05000661A - Composicion farmaceutica estable que comprende eritropoyetina. - Google Patents

Composicion farmaceutica estable que comprende eritropoyetina.

Info

Publication number
MXPA05000661A
MXPA05000661A MXPA05000661A MXPA05000661A MXPA05000661A MX PA05000661 A MXPA05000661 A MX PA05000661A MX PA05000661 A MXPA05000661 A MX PA05000661A MX PA05000661 A MXPA05000661 A MX PA05000661A MX PA05000661 A MXPA05000661 A MX PA05000661A
Authority
MX
Mexico
Prior art keywords
erythropoietin
pharmaceutical composition
stable pharmaceutical
stable
stabilised
Prior art date
Application number
MXPA05000661A
Other languages
English (en)
Inventor
Alenka Paris
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of MXPA05000661A publication Critical patent/MXPA05000661A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona una nueva composicion farmaceutica estable de eritropoyetina (EPO) que es estabilizada con PVP.
MXPA05000661A 2002-07-17 2002-11-08 Composicion farmaceutica estable que comprende eritropoyetina. MXPA05000661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200176A SI21257A (sl) 2002-07-17 2002-07-17 Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
PCT/IB2002/004690 WO2004006948A1 (en) 2002-07-17 2002-11-08 Stable pharmaceutical composition comprising erythropoietin

Publications (1)

Publication Number Publication Date
MXPA05000661A true MXPA05000661A (es) 2005-08-19

Family

ID=30113491

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000661A MXPA05000661A (es) 2002-07-17 2002-11-08 Composicion farmaceutica estable que comprende eritropoyetina.

Country Status (13)

Country Link
US (1) US8648175B2 (es)
EP (1) EP1536822B1 (es)
JP (1) JP4979191B2 (es)
CN (1) CN100425283C (es)
AR (1) AR040600A1 (es)
AT (1) ATE330623T1 (es)
AU (1) AU2002368075B2 (es)
CA (1) CA2492470C (es)
DE (1) DE60212728T2 (es)
ES (1) ES2268166T3 (es)
MX (1) MXPA05000661A (es)
SI (1) SI21257A (es)
WO (1) WO2004006948A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100852821B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
JP5553506B2 (ja) * 2006-03-22 2014-07-16 中外製薬株式会社 エリスロポエチン溶液製剤
WO2014199373A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc- macrophage activating factor and uses thereof
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
WO2023098844A1 (zh) * 2021-12-03 2023-06-08 杰科（天津）生物医药有限公司 一种制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS63146828A (ja) * 1986-07-18 1988-06-18 Chugai Pharmaceut Co Ltd 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
JPH0952844A (ja) * 1995-08-10 1997-02-25 Amano Pharmaceut Co Ltd 酵素含有内服液剤
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation

Also Published As

Publication number Publication date
SI21257A (sl) 2004-02-29
DE60212728D1 (de) 2006-08-03
JP2006501193A (ja) 2006-01-12
ATE330623T1 (de) 2006-07-15
CA2492470A1 (en) 2004-01-22
EP1536822B1 (en) 2006-06-21
CN1638791A (zh) 2005-07-13
EP1536822A1 (en) 2005-06-08
JP4979191B2 (ja) 2012-07-18
AR040600A1 (es) 2005-04-13
DE60212728T2 (de) 2007-06-28
ES2268166T3 (es) 2007-03-16
AU2002368075B2 (en) 2007-07-05
US20050238720A1 (en) 2005-10-27
AU2002368075A1 (en) 2004-02-02
WO2004006948A1 (en) 2004-01-22
CA2492470C (en) 2012-08-28
US8648175B2 (en) 2014-02-11
CN100425283C (zh) 2008-10-15

Similar Documents

Publication Publication Date Title
MXPA04001560A (es) Premezclas de glp-1 e insulina basal.
SV2003001076A (es) Compuestos y procedimientos antitumorales ref. x-14776
PT1671949E (pt) Piridinilaminas substituídas
MXPA04000877A (es) Derivados retinoides con actividades antiangiogenicas, antitumorales y proapoptoticas.
AU2002248464A1 (en) Stabilized insulin formulations
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
GB0124627D0 (en) Novel compounds
WO2003027081A3 (en) NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
AU2002360493A1 (en) Active electrode composition with graphite additive
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
AU148080S (en) Spray pump head
EP1445253A4 (en) 4,4-DIFLUOR-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES AND THEIR SALTS
IL173929A (en) Kahlalid F analogs and their pharmacy preparations
AU148079S (en) Spray pump head
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
NO20021409D0 (no) Hastighets-kontrollerte partikler
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
SG136958A1 (en) Antagonistic analogs of gh-rh (2003)
JO2369B1 (en) New cyclohexyl sulfonate
TW200517117A (en) Stabilized compositions containing an oxygen-labile active agent
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
MXPA05000661A (es) Composicion farmaceutica estable que comprende eritropoyetina.
AU2003291972A8 (en) Pharmaceutical compositions comprising insulin and legends of insulin hexamer
AU148078S (en) Bottle
AU2002342498A1 (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration